Thuy-Van P. Hang, Zachary Spiritos, Anthony M. Gamboa, Zhengjia Chen, Seth Force, Vaishali Patel, Saurabh Chawla, Steven Keilin, Nabil F. Saba, Bassel El-Rayes, Qiang Cai, Field F. Willingham
Clin Endosc 2022;55(3):372-380. Published online February 11, 2022
Background /Aims: Endoscopic resection has become the preferred treatment approach for select early esophageal adenocarcinoma (EAC); however, the epidemiology of early stage disease has not been well defined.
Methods Surveillance Epidemiology and End Results (SEER) data were analyzed to determine age-adjusted incidence rates among major epithelial carcinomas, including EAC, from 1973 to 2017. The percent change in incidence over time was compared according to tumor subtype. Early T-stage, node-negative EAC without metastasis was examined from 2004 to 2017 when precise T-stage data were available.
Results The percent change in annual incidence from 1973 to 2017 was 767% for EAC. Joinpoint analysis showed that the average annual percent change in EAC from 1973 to 2017 was 5.11% (95% confidence interval, 4.66%–5.56%). The annual percent change appeared to plateau between 2004 and 2017; however, early EAC decreased from 2010 to 2017, with an annual percent change of -5.78%.
Conclusions There has been a 7-fold increase in the incidence of EAC, which was significantly greater than that of the other major epithelial malignancies examined. More recently, the incidence of early EAC has been decreasing. Approximately one in five patients has node negative, potentially resectable early stage disease.
Citations
Citations to this article as recorded by
Predictors of Understaging with EUS and PET-CECT in Early Esophageal Carcinoma Karthik Venkataramani, Sabita Jiwnani, Devayani Niyogi, Virendrakumar Tiwari, C. S. Pramesh, George Karimundackal Journal of Gastrointestinal Cancer.2025;[Epub] CrossRef
Histology Shift in Esophageal Cancer Between Biopsies and Resections After Neoadjuvant Therapy: A Pilot Study Tieying Hou, Zhaohai Yang, Qingzhao Zhang, Xuchen Zhang, Xiaoyan Liao, Jingmei Lin International Journal of Surgical Pathology.2024; 32(5): 920. CrossRef
Concise Commentary: It’s All Downhill from Here—How Diagnostic and Therapeutic Advances May Decrease the Incidence Rates of Gastroesophageal Junction and Esophageal Adenocarcinoma Anthony Gamboa, Rishi Naik Digestive Diseases and Sciences.2024; 69(1): 254. CrossRef
Descriptive Epidemiology of Early-Onset Gastrointestinal Cancers in Iran, 2014-2018 Mohammad Sadra Gholami Chahkand, Fatemeh Esmaeilpour Moallem, Fatemeh Ghasemi-Kebria, Reza Malekzadeh, Gholamreza Roshandel, Mohammad Taher Middle East Journal of Digestive Diseases.2024; 16(1): 28. CrossRef
A Systematic Review and Meta-analysis of the Relationship between Statin Intake
and Esophageal Cancer Armin Khaghani, Karamali Kasiri, Saeid Heidari-Soureshjani, Catherine M.T. Sherwin, Hossein Mardani-Nafchi Anti-Cancer Agents in Medicinal Chemistry.2024; 24(14): 1029. CrossRef
Long-term outcomes of endoscopic submucosal dissection for early esophageal adenocarcinoma in the Eastern population: a comprehensive analysis Xiao-han Jiang, Qing Liu, Min Fu, Cheng-fan Wang, Rui-han Zou, Li Liu, Min Wang Journal of Gastrointestinal Surgery.2024; 28(12): 1988. CrossRef
Inhibition of Insulin-like Growth Factor 1 Receptor/Insulin Receptor Signaling by Small-Molecule Inhibitor BMS-754807 Leads to Improved Survival in Experimental Esophageal Adenocarcinoma Md Sazzad Hassan, Chloe Johnson, Saisantosh Ponna, Dimitri Scofield, Niranjan Awasthi, Urs von Holzen Cancers.2024; 16(18): 3175. CrossRef
Epidemiologie der Adenokarzinome des Ösophagus und des ösophagogastralen Übergangs Sabine Luttmann, Andrea Eberle, Joachim Hübner Die Onkologie.2023; 29(6): 470. CrossRef
Evaluation of Esophageal Dysphagia in Elderly Patients Khanh Hoang Nicholas Le, Eric E. Low, Rena Yadlapati Current Gastroenterology Reports.2023; 25(7): 146. CrossRef
Molecular Biology and Clinical Management of Esophageal Adenocarcinoma Shulin Li, Sanne Johanna Maria Hoefnagel, Kausilia Krishnawatie Krishnadath Cancers.2023; 15(22): 5410. CrossRef
Progress in Clinical Management of Esophago-Jejunal Anastomotic Fistula with Total Gastrectomy for Adenocarcinoma of the Esophagogastric Junction 天伟 赖 Advances in Clinical Medicine.2023; 13(11): 17210. CrossRef
Cranberry Proanthocyanidins Mitigate Reflux-Induced Transporter Dysregulation in an Esophageal Adenocarcinoma Model Yun Zhang, Katherine M. Weh, Bridget A. Tripp, Jennifer L. Clarke, Connor L. Howard, Shruthi Sunilkumar, Amy B. Howell, Laura A. Kresty Pharmaceuticals.2023; 16(12): 1697. CrossRef
Lessons learned in clinical epidemiology of esophageal adenocarcinoma Hye Kyung Jung Clinical Endoscopy.2022; 55(3): 365. CrossRef
Background /Aims: There are conflicting opinions regarding the management of recurrent acute pancreatitis (RAP). While some physicians recommend endoscopic retrograde cholangiopancreatography (ERCP) in this setting, others consider it to be contraindicated in patients with RAP. The aim of this study was to assess the practice patterns and clinical features influencing the management of RAP in the US.
Methods An anonymous 35-question survey instrument was developed and refined through multiple iterations, and its use was approved by our Institutional Review Board. The survey was distributed via email to 408 gastroenterologists to assess the practice patterns in the management of RAP in multiple clinical scenarios.
Results The survey was completed by 65 participants representing 36 of the top academic/tertiary care centers across the country. Approximately 90.8% of the participants indicated that they might offer or recommend ERCP in the management of RAP. Multinomial logistic regression analysis revealed that ductal dilatation and presence of symptoms were the most predictive variables (p<0.001) for offering ERCP.
Conclusions A preponderance of the respondents would consider ERCP among patients with RAP presenting to tertiary care centers in the US. Ductal dilatation, presence of symptoms, and pancreas divisum significantly increased the likelihood of a recommendation for ERCP
Citations
Citations to this article as recorded by
Controversies in ERCP Christoph F. Dietrich, Noor L. Bekkali, Sean Burmeister, Yi Dong, Simon M. Everett, Michael Hocke, Andre Ignee, Wei On, Srisha Hebbar, Kofi Oppong, Siyu Sun, Christian Jenssen, Barbara Braden Endoscopic Ultrasound.2022; 11(1): 27. CrossRef
Controversies in ERCP Christoph F. Dietrich, Noor L. Bekkali, Sean Burmeister, Yi Dong, Simon M. Everett, Michael Hocke, Andre Ignee, Wei On, Srisha Hebbar, Kofi Oppong, Siyu Sun, Christian Jenssen, Barbara Braden Endoscopic Ultrasound.2022; 11(3): 186. CrossRef
Biliary hitch and ride technique for blind pancreatic duct cannulation Juan J. Vila, Juan Carrascosa, Ignacio Fernández-Urién, Paul Yeaton, Gonzalo González, Leire Aburruza, José Manuel Zozaya Endoscopy.2021; 53(01): E29. CrossRef
Endoscopic Retrograde Cholangiopancreatography in Recurrent Acute Pancreatitis: Determining the Optimal Subgroup of Patients in Whom the Procedure is Beneficial Tae Yoon Lee, Takuji Iwashita Clinical Endoscopy.2020; 53(1): 5. CrossRef
Esophageal cancer has a poor overall prognosis and is frequently diagnosed at a late stage. Conventional treatment for metastatic esophageal cancer involves chemotherapy and radiation. Local disease control plays a significant role in improving survival. Endoscopic spray cryotherapy is a novel modality that involves freezing and thawing to produce local ablation of malignant tissue via ischemic mechanisms. Spray cryotherapy has been shown to be effective, particularly for early T-stage, superficial esophageal adenocarcinomas. We present the case of a 72-year-old-male with locally recurrent stage IV esophageal adenocarcinoma and long-term survival of 7 years to date, with concurrent chemoradiation and serial cryoablation. He remains asymptomatic and continues to undergo chemotherapy and sequential cryoablation. The findings highlight the long-term safety and efficacy of cryotherapy in combination with chemoradiation, and suggest that cryoablation may have an additive role in the treatment of advanced stage esophageal adenocarcinoma.
Citations
Citations to this article as recorded by
Endoscopic Palliative Therapies for Esophageal Cancer Youssef Y. Soliman, Madappa Kundranda, Toufic Kachaamy Gastrointestinal Endoscopy Clinics of North America.2024; 34(1): 91. CrossRef
Role of oesophageal balloon cryoablation in combination with personalised immunotherapy to achieve luminal control in metastatic oesophageal cancer: a case report Benjamin Charles Norton, Apostolis Papaefthymiou, Andrea Telese, Margaret Duku, Imran Chaudhry, Alberto Murino, Gavin Johnson, Charles Murray, Rehan Haidry Frontline Gastroenterology.2024; 15(4): 336. CrossRef
Cryoballoon ablation as salvage therapy after nonradical resection of a high-risk T1b esophageal adenocarcinoma: a case report Charlotte N. Frederiks, Jolanda M.W. van de Water, Gati Ebrahimi, Bas L.A.M. Weusten European Journal of Gastroenterology & Hepatology.2022; 34(3): 354. CrossRef
Surgery to the primary tumor is associated with improved survival of patients with metastatic esophageal cancer: propensity score-matched analyses of a large retrospective cohort Rui Zhang, Jiahua Zou, Ping Li, Qin Li, Yunfeng Qiao, Jianglong Han, Kejie Huang, Peng Ruan, Huiqing Lin, Qibin Song, Zhenming Fu Diseases of the Esophagus.2019;[Epub] CrossRef